Plus therapeutics' reyobiq™ shows clinical benefit and safety in the respect-lm clinical trial for patients with leptomeningeal metastases (lm)

Multiple long-term lm survivors in those patients receiving multiple doses of reyobiq rna sequencing data show early tumor apoptosis and activation of innate immune responses updated respect data presented at the 2025 nuclear medicine and neurooncology conference houston, may 14, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, announces the presentation of new data on its lead drug reyobiq™ (rhenium re186 obisbemeda) during both an oral presentation and a poster presented at the nuclear medicine and neurooncology conference. the meeting was held may 9-10, 2025 in vienna, austria.
PSTV Ratings Summary
PSTV Quant Ranking